Research & Development

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg...

AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company,...

Within the rapidly evolving world of cancer treatment and the excitement surrounding immuno-oncology, it is more important than ever to...

AstraZeneca, along with MedImmune, the company’s global biologics research and development arm, will illustrate the strength and depth of research...

The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies –AMAGINE-2 and...

AstraZeneca and Eli Lilly and Company (Lilly) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies...

Eli Lilly and Company (NYSE: LLY) and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data...

Allergan plc (NYSE: AGN), a leading global specialty pharmaceutical company, today announced a multi-year research collaboration with Humana Inc. (NYSE:...

We were pioneers among Indian pharmaceutical companies to see tremendous value in investing in research & development (R&D). Our early...

In addition to ensuring that Amgen's investment decisions are based on compelling science, we are reengineering our processes to operate...